Controlled.

Conformable.

Listening carefully to our physician partners, our engineers and scientists have applied their spirit of innovation to the complexities of endovascular repair. The result: a new system that offers clinicians greater control for durable outcomes.



We lead the way in TEVAR innovation.

- The first thoracic stent graft approved in Europe, U.S., and Japan*
- The first TEVAR device to reach 100.000 devices distributed
- The first device approved for endovascular treatment of aneurysms, transections, and Type B dissections
- The first to feature a new delivery system that offers controlled, staged deployment
- 20 years of TEVAR experience
- * Conformable GORE® TAG® Device

Learn more at goremedical.com/predictable



W. L. GORE & ASSOCIATES, INC.


Flagstaff, AZ 86004

+65.67332882 (Asia Pacific) 00800.6334.4673 (Europe) 800.437.8181 (United States) 928.779.2771 (United States)

goremedical.com

Products listed may not be available in all markets.

GORE®, ACTIVE CONTROL, TAG®, and designs are trademarks of W. L. Gore & Associates, © 2017 W. L. Gore & Associates, Inc. AW0973-EN1 SEPTEMBER 2017




Introducing the GORE® TAG® Conformable Thoracic Stent Graft with




Even patients with complex anatomical challenges such as acute aortic angles can benefit from the GORE® ACTIVE **CONTROL System.**

Now, endovascular repair of aneurysms, transections, and Type B dissections can be carried out with greater precision than ever.



The GORE® ACTIVE CONTROL System is the first to feature a new delivery system that offers controlled, staged deployment.



Patients have individual anatomies with unique challenges. The GORE® ACTIVE CONTROL System enhances the exceptional conformability of the stent graft; facilitating the optimized wall apposition that the Conformable GORE® TAG® Device is renowned for.



Through five-year follow-up* (N = 217)Procedural survival 100% Fracture 0% 30-day **95.4%** Aortic rupture Freedom from associated with treated 1.8% Migration 0% device-related 93.1% reintervention area

Predictable.

Built on the established success of the Conformable GORE® TAG® Device that has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).*

Proximal partially

uncovered stents

for wall apposition

in highly angulated

anatomy

Fully supported

graft material for

low spring-back

Purpose-built to deliver new levels of control, with precise placement and trusted conformability.

Sheathless delivery catheter facilitates passage and access through tortuous thoracic anatom

Fully covered distal end for decreased risk of septum perforation in Type B dissection

Radial fit

for customized

oversizing based on

patient anatomy

Single-sheath insertion minimizes vessel trauma and the potential for rupture which can occur with multiple sheath

with GORE® ACTIVE CONTROL System is designed to optimize accuracy, angulation, and apposition

Controlled deployment

insertions